Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Usefulness of post bronchodilator FVC in the evaluation and spirometric evolution of COPD patients

Alejandro Raimondi, Alejandro Carlos Raimondi
European Respiratory Journal 2013 42: P797; DOI:
Alejandro Raimondi
1Pulmonary Division, Hospital De Clínicas "José De San Martín", Buenos Aires, Argentina
3Internal Medicine, CEMIC, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alejandro Carlos Raimondi
2Pulmonary and Critical Care, Sanatorio Mater Dei, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Tables

  • Table1

     Value (total 49)
    Age, years68±8
    Female sex, %57
    BMI, kg.m-223±3
    GOLD Stage I, %8
    -Stage II, %49
    -Stage III, %29
    -Stage IV, %14
    Smoking history, pack/year38±11
    Annual change of FEV1, ml/year-50±88
    FEV1 reversible group, %16.3
    -Annual change of FEV1, ml/year-142±113
    FVC reversible group, %38.8
    -Annual change of FEV1, ml/year-94±86
    • Data are presented as mean ± SD unless otherwise indicated. BMI: Body mass index.

Previous
Back to top
Vol 42 Issue Suppl 57 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Usefulness of post bronchodilator FVC in the evaluation and spirometric evolution of COPD patients
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Usefulness of post bronchodilator FVC in the evaluation and spirometric evolution of COPD patients
Alejandro Raimondi, Alejandro Carlos Raimondi
European Respiratory Journal Sep 2013, 42 (Suppl 57) P797;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Usefulness of post bronchodilator FVC in the evaluation and spirometric evolution of COPD patients
Alejandro Raimondi, Alejandro Carlos Raimondi
European Respiratory Journal Sep 2013, 42 (Suppl 57) P797;
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Should pseudomonas aeruginosa be the main target in bronchiectasis?
  • X-Tab: Non-interventional study to assess patient-related mid-term outcomes of omalizumab therapy in severe allergic asthmatic patients
  • Clinical Impact of Gensini score in chronic obstructive pulmonary disease (COPD)
Show more 5.2 Monitoring Airway Disease

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society